Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Lori

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Journal of Virology|February 12, 2002
Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytesGiampiero Piccinini, Andrea Foli, Giuditta Comolli, et al.
Vaccine|March 10, 2005
DermaVir, a novel HIV immunisation technologyFranco Lori, Jeffrey Trocio, Nyasha Bakare, et al.
Springer Seminars in Immunopathology|October 21, 2006
Cytokine-adjuvanted HIV-DNA vaccination strategiesFranco Lori, David B Weiner, Sandra A Calarota, et al.
Plos One|November 10, 2022
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patientsDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
Plos One|December 5, 2024
Correction: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patientsDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
Vaccine|November 27, 2010
A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIVEszter Somogyi, Jianqing Xu, Agnes Gudics, et al.
Vaccine|May 9, 2008
IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccineSandra A Calarota, Anlan Dai, Jeffrey N Trocio, et al.
AIDS (London, England)|July 2, 2005
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanismsFranco Lori, Andrea Foli, Antonella Groff, et al.
Current Medicinal Chemistry|September 3, 2024
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive CancersDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
HIV Clinical Trials|April 27, 2002
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responsesFranco Lori, Andrea Foli, Renato Maserati, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Journal of Virology|February 12, 2002
Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytesGiampiero Piccinini, Andrea Foli, Giuditta Comolli, et al.
Vaccine|March 10, 2005
DermaVir, a novel HIV immunisation technologyFranco Lori, Jeffrey Trocio, Nyasha Bakare, et al.
Springer Seminars in Immunopathology|October 21, 2006
Cytokine-adjuvanted HIV-DNA vaccination strategiesFranco Lori, David B Weiner, Sandra A Calarota, et al.
Plos One|November 10, 2022
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patientsDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
Plos One|December 5, 2024
Correction: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patientsDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
Vaccine|November 27, 2010
A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIVEszter Somogyi, Jianqing Xu, Agnes Gudics, et al.
Vaccine|May 9, 2008
IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccineSandra A Calarota, Anlan Dai, Jeffrey N Trocio, et al.
AIDS (London, England)|July 2, 2005
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanismsFranco Lori, Andrea Foli, Antonella Groff, et al.
Current Medicinal Chemistry|September 3, 2024
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive CancersDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
HIV Clinical Trials|April 27, 2002
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responsesFranco Lori, Andrea Foli, Renato Maserati, et al.
Pageof 5